APA (7th ed.) Citation

United States. Food and Drug Administration. Office of Combination Products, Center for Devices and Radiological Health (U.S.), & Center for Drug Evaluation and Research (U.S.). (2008). Guidance for industry: New contrast imaging indication considerations for devices and approved drug and biological products. U.S. Dept. of Health and Human Services, Food and Drug Administration, Office of Combination Products (OCP) in Office of Commissioner : Center for Devices and Radiological Health (CDRH) : Center for Drug Evaluation and Research (CDER).

Chicago Style (17th ed.) Citation

United States. Food and Drug Administration. Office of Combination Products, Center for Devices and Radiological Health (U.S.), and Center for Drug Evaluation and Research (U.S.). Guidance for Industry: New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products. Rockville, MD: U.S. Dept. of Health and Human Services, Food and Drug Administration, Office of Combination Products (OCP) in Office of Commissioner : Center for Devices and Radiological Health (CDRH) : Center for Drug Evaluation and Research (CDER), 2008.

MLA (9th ed.) Citation

United States. Food and Drug Administration. Office of Combination Products, et al. Guidance for Industry: New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products. U.S. Dept. of Health and Human Services, Food and Drug Administration, Office of Combination Products (OCP) in Office of Commissioner : Center for Devices and Radiological Health (CDRH) : Center for Drug Evaluation and Research (CDER), 2008.